Treating Kidney Disease in Patients with APOL1

If you are 18-65 years old, diagnosed with kidney disease, and not diabetic, you may be eligible for a clinical trial that is testing an investigational medication to treat APOL1-Mediated Kidney Disease (AMKD). AMKD is caused by genetic variations, which occur commonly in people with African ancestry, and can increase your risk of reaching end-stage kidney disease. Interested participants will receive investigational genetic testing to see if they carry the disease-causing APOL1 genes. Qualified participants will be compensated for study-related time and reimbursement for travel.

Patients must be between the ages of 18 and 65 years (inclusive) and have a BMI of 18.0 to 40.0 kg/m² and a total body weight ≥ 40kg. Patients must also have an estimated glomerular filtration rate (GFR) between 25-75 mL/min.1.73m² on Day 1.

Exclusion criteria includes a history of: diabetes, organ transplantation, cancer (except squamous cell skin cancer and basal cell skin cancer, and Stage 0 cervical carcinoma in situ), or positive blood serum for HIV-1 or HIV-2. Additionally, patients who test positive for hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) RNA, or HIV during screening will be excluded.